Alejo R. V. R.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of MEDI5752 in Patients with Advanced Solid Tumors: A Clinical Trial
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- Phase II Study of Sasanlimab and Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
Data & Insights
Has run more than one trial at 292 of 566 partner sites.
Specializations
Prostate Cancer Research
The investigator specializes in various forms of prostate cancer treatment, with particular emphasis on metastatic castration-resistant prostate cancer (mCRPC) and hormone-naïve prostate cancer.
- Advanced therapeutic combinations
- Hormone therapy optimization
- Bone metastasis management
Research includes innovative approaches using androgen receptor pathway inhibitors and combination therapies for various stages of disease progression.
Bladder Cancer Studies
Focuses on advancing treatment options for urothelial tract tumors and non-muscle invasive bladder cancer (NMIBC), including novel therapeutic approaches.
- Neoadjuvant immunotherapy
- BCG-unresponsive disease
- Advanced urothelial cancer
Investigates both early-stage interventions and treatments for locally advanced and metastatic disease.
Advanced Solid Tumors
Conducts research on novel therapeutic approaches for various solid tumors, including clear cell renal cell carcinoma and other advanced malignancies.
- Immunotherapy combinations
- Targeted therapies
- Novel drug development
Explores innovative treatment strategies using fixed-dose combinations and emerging therapeutic agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.